JOURNAVX
Oral nonopioid indicated for the treatment of moderate-to-severe acute pain, including postoperative pain, in adults
journavxhcp.com Industry Software / Life Sciences & Biotech
- Monthly visits
- 97.1K
- Down37.6%MoMOct 2026
- Public revenue
- Undisclosed
- No public revenue evidence yet
- Entry price
- Unknown
- No monthly subscription pricing
- Creators
- Unlinked
- No verified creators
- Launched
- 2y ago
- 2024-04-19 · Est.
Traffic
Marketing moves
Launches, search & content, referrals, promotionsNew product launchLaunch
Apr 19, 2024 · 2y agoWebsite
Traffic sources
Traffic breakdown
Channels
- Paid Search48%
- Display Ads28%
- Organic Search13%
- Direct5%
- Other5%
Countries
- United States100%
Search
Domain authority —Domain registered 2024-04-19
| Keyword | Monthly volume |
|---|---|
| journavx | 50.9K |
| suzetrigine | 14.2K |
| journavx (suzetrigine) | 3,190 |
| journavx mechanism of action | 540 |
| what insurances cover journavx | 410 |
Traffic data: Vaneform
Pricing
Pricing page not identified yet, or no public pricing listed.
Pages & changes
Key pages
Weekly snapshots- Homewww.journavxhcp.com/ Snapshot 2026-11-16
- Featureswww.journavxhcp.com/safety Snapshot 2026-11-16
Changes
- Nov 11 · 5d ago
Homepage tagline changed to “JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain, including postoperative pain, in adults”Positioning
See how JOURNAVX works→JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain, including postoperative pain, in adults
At the time: 97.1K visits/mo6 concurrent moves - Nov 1 · 16d ago
Homepage headline (H1) changed to “JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain, includin...”Positioning
JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain in adults→JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain, includin...
At the time: 97.1K visits/mo6 concurrent moves
Questions & evidence
- How much website traffic does JOURNAVX get?
- Vaneform estimates 97.1K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
- What is JOURNAVX and what platforms does it support?
- JOURNAVX is catalogued under Life Sciences & Biotech: Oral nonopioid indicated for the treatment of moderate-to-severe acute pain, including postoperative pain, in adults. Supported platforms: Web.
Related products in this category
These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.
| Product | Entry price | Visits | Revenue |
|---|---|---|---|
| Fierce BiotechMatureFierce Biotech News & Reports | — | 879.4K | Undisclosed |
| 田辺ファーマ株式会社Develops innovative medicines for people facing illness. | — | 393.4K | Undisclosed |
| Certified-PepThe Most Trusted Name in Research Peptides | — | 323.2K | Undisclosed |
| EvidentWe are guided by the scientific spirit. Evident creates advanced life science and industrial microscopy solutions that help make the world… | — | 305.9K | Undisclosed |
| AlphaFold ServerAlphaFold Server – powered by AlphaFold 3 – provides accurate structure predictions for how proteins interact with other molecules, like DNA | — | 299.4K | Undisclosed |
| RxTra ClinicalYour Clinical Trials Concierge. | — | 296.9K | Undisclosed |